Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations - Pilla Reddy - 2019 - Clinical Pharmacology & Therapeutics - Wiley Online Library
How To Take LYNPARZA® (olaparib)
Lynparza, INN - olaparib
206162Orig1s000
Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials - Radiotherapy and Oncology
PARP Inhibitor Improves Odds for Women With Ovarian Cancer and More Cancer News From ASCO's Virtual Annual Meeting | Everyday Health
Lynparza, INN - olaparib
Lynparza, INN-olaparib
How To Take LYNPARZA® (olaparib)
PDF) Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations: PBPK modeling for olaparib dosing recommendations
Australian Public Assessment Report for Olaparib
How To Take LYNPARZA® (olaparib)
Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations - Pilla Reddy - 2019 - Clinical Pharmacology & Therapeutics - Wiley Online Library
Investor science event: Late-stage pipeline webcast
Australian public assessment for Olaparib
PDF) PARP inhibitors as potential therapeutic agents for various cancers: Focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers
Australian public assessment for Olaparib
206162Orig1s000
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies - Clinical Therapeutics
Efamat Efavirenz 600MG Tablets Exporter, Manufacturer
Lynparza, INN-olaparib
Lynparza, INN - olaparib
Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies
